Biopharma News

Jun 13, 2018
By BioPharm International Editors
Alexion Pharmaceuticals and Complement Pharma will partner to develop a preclinical C6 complement inhibitor to treat neurodegenerative disorders.
Jun 13, 2018
By BioPharm International Editors
WuXi Biologics will invest $60 million to establish a biologics production facility in Massachusetts.
Jun 13, 2018
By BioPharm International Editors
The companies will partner in research for HIV and hepatitis B immunotherapies, and Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead.
Jun 13, 2018
By BioPharm International Editors
Bayer completed its acquisition of Monsanto, the largest in Bayer’s history.
Jun 07, 2018
By BioPharm International Editors
The company will provide the first FlexFactory manufacturing platform for TCR T-cell therapy manufacturing.
Jun 05, 2018
By BioPharm International Editors
The agency has approved Mylan’s Fulphila (pegfilgrastim-jmdb) as the first US-approved biosimilar to Amgen’s Neulasta (pegfilgrastim) to reduce infection risk during cancer treatment.
Jun 04, 2018
By BioPharm International Editors
The agency has recommended approval of three biosimilar adalimumab products from Novartis, referencing AbbVie’s Humira, and a biosimilar trastuzumab from Pfizer, referencing Roche’s Herceptin.
Jun 04, 2018
By BioPharm International Editors
EMA has recommended marketing authorization for Aimovig (erenumab), a new treatment for migraine.
May 30, 2018
By BioPharm International Editors
GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.
May 30, 2018
By BioPharm International Editors
Bayer received conditional approval from the Antitrust Division of the United States Department of Justice to acquire Monsanto in a deal worth $66 billion.
native1_300x100
lorem ipsum